Chemotherapy-associated hepatotoxicity: how concerned should we be?

References

• Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg.239(6), 818–825 (2004).
   PubMed Web of Science ®Google Scholar
• Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg.235(6), 759–766 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann. Surg.240(3), 438–447 (2004).
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg.241(5), 715–722 (2005).
   PubMed Web of Science ®Google Scholar
• Bilchik AJ, Poston G, Curley SA et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J. Clin. Oncol.23(36), 9073–9078 (2005).
   PubMed Web of Science ®Google Scholar
• Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J. Gastrointest. Surg.7(8), 1082–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Kooby DA, Fong Y, Suriawinata A et al. Impact of steatosis on perioperative outcome following hepatic resection. J. Gastrointest. Surg.7(8), 1034–1044 (2003).
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol.15(3), 460–466 (2004).
   PubMed Web of Science ®Google Scholar
• Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol.24(31), 4983–4990 (2006).
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol.24(13), 2065–2072 (2006).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC Intergroup randomized Phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J. Clin. Oncol.25, 18S (2007).
   Google Scholar
• Karakousis G, Fong Y. The case for selective use of pre-operative chemotherapy for hepatic colorectal metastases: more is not always better. Ann. Surg. Oncol.16(8), 2086–2088 (2009).
   PubMedGoogle Scholar
• Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg.240(4), 644–657 (2004).
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis.22(2), 137–144 (2002).
   PubMed Web of Science ®Google Scholar
• Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol.44(1), 197–208 (2006).
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis.22(1), 27–42 (2002).
   PubMed Web of Science ®Google Scholar
• Grivicich I, Regner A, da Rocha AB et al. The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy51(2–3), 93–102 (2005).
   PubMed Web of Science ®Google Scholar
• Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion6(1), 1–28 (2006).
   PubMed Web of Science ®Google Scholar
• Custodio JB, Cardoso CM, Santos MS, Almeida LM, Vicente JA, Fernandes MA. Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology259(1–2), 18–24 (2009).
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J. Am. Coll. Surg.202(1), 199–200 (2006).
   PubMedGoogle Scholar
• Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J. Am. Coll. Surg.200(6), 845–853 (2005).
   PubMed Web of Science ®Google Scholar
• Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur. J. Surg. Oncol.34(11), 1231–1236 (2008).
   PubMedGoogle Scholar
• Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann. Surg.243(1), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Sebagh M, Plasse M, Levi F, Adam R. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity? Ann. Oncol.16(2), 331 (2005).
   PubMed Web of Science ®Google Scholar
• Nakano H, Oussoultzoglou E, Rosso E et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann. Surg.247(1), 118–124 (2008).
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology49(1), 306–317 (2009).
   PubMed Web of Science ®Google Scholar
• Sahajpal A, Vollmer CM Jr, Dixon E et al. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J. Surg. Oncol.95(1), 22–27 (2007).
   PubMedGoogle Scholar
• Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J. Gastrointest. Surg.11(7), 860–868 (2007).
   PubMed Web of Science ®Google Scholar
• Ribero D, Wang H, Donadon M et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer110(12), 2761–2767 (2007).
   PubMed Web of Science ®Google Scholar
• Kesmodel SB, Ellis LM, Lin E et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J. Clin. Oncol.26(32), 5254–5260 (2008).
   PubMed Web of Science ®Google Scholar
• D’Angelica M, Kornprat P, Gonen M et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case–control study. Ann. Surg. Oncol.14(2), 759–765 (2007).
   PubMed Web of Science ®Google Scholar
• Oliva MR, Mortele KJ, Segatto E et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J. Comput. Assist. Tomogr.30(1), 37–43 (2006).
   PubMedGoogle Scholar
• Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br. J. Cancer77(11), 2008–2011 (1998).
   PubMed Web of Science ®Google Scholar
• Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann. Surg.243(1), 8–9 (2006).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet371(9617), 1007–1016 (2008).
   PubMed Web of Science ®Google Scholar
• Lee CK, Park KK, Hwang JK, Lee SK, Chung WY. The extract of Prunus persica flesh (PPFE) attenuates chemotherapy-induced hepatotoxicity in mice. Phytother. Res.22(2), 223–227 (2008).
   PubMedGoogle Scholar
• Lee CK, Park KK, Hwang JK, Lee SK, Chung WY. The pericarp extract of Prunus persica attenuates chemotherapy-induced acute nephrotoxicity and hepatotoxicity in mice. J. Med. Food11(2), 302–306 (2008).
   PubMedGoogle Scholar
• Brouquet A, Benoist S, Julie C et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery145(4), 362–371 (2009).
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med.355(22), 2297–2307 (2006).
   PubMed Web of Science ®Google Scholar